Ramipril, Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus

• Status: Completed
• Trial end date: 2013-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this study was to evaluate the effect of ramipril on the endothelial function and on the number of endothelial progenitor cells (EPCs) in systemic lupus erythematosus (SLE) patients.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Federal University of São Paulo
• Collaborator: Fundação de Amparo à Pesquisa do Estado de São Paulo
• Treatments: Angiotensin-Converting Enzyme Inhibitors; Enzyme Inhibitors; Ramipril

Criteria

Inclusion Criteria:

• SLE according 1997 modified American College Rheumatology criteria

• age older than 18 years

• stable treatment for lupus for at least 3 months

Exclusion Criteria:

• previous coronary artery disease

• hypertension

• dyslipidemia (LDL>149 mg/dL)

• renal insufficiency (creatinine ≥1.4 mg/dL)

• diabetes

• smoking

• obesity (BMI≥30)

• pregnancy

• menopause

• patients taking statins or angiotensin convertor enzyme inhibitor within the last 6 months